HealthTech Bio Actives (HTBA) has announced the construction of a new diosmin production plant at its research, development and manufacturing centre in Murcia, Spain.
With an investment of more than €6m, the new plant will enable the company to increase its diosmin production capacity by more than 40%, supporting its sustainable growth plans.
For pharmaceutical and nutraceutical manufacturers, this paves the way for further innovation with diosmin, an ingredient that can enhance venous tone and circulation and address vascular discomfort.
Advancing diosmin innovation
As the world’s largest producer of diosmin, HTBA manufactures diosmin as an active pharmaceutical ingredient (API) for the treatment of chronic cardiovascular disease (CVD), varicose veins, spider veins and haemorrhoids, as well as a food supplement ingredient, DiosVein, to keep legs healthy.
In line with the company’s long-term strategic growth plans, through this investment, HTBA continues to strengthen its diosmin innovation and manufacturing capabilities.
"This latest investment further reinforces HTBA’s standing as an international leader in the production of flavonoids, supporting innovation in the health and wellness sector," comments Alexandre Valls-Coma, CEO at HTBA.
”By prioritising innovation and sustainable manufacturing, during the last few years, the company has entered a period of remarkable growth."
"This project further strengthens our expansion and competitiveness in a highly regulated and demanding global environment."
Facilitating greater efficiency and sustainability
As part of HTBA’s ongoing commitment to zero-waste, the company uses solvent-free manufacturing for its diosmin that yields no remaining organic solvents and ensures compliance with the highest quality standards.
The new manufacturing plant will further consolidate HTBA’s position as the only company in the world capable of manufacturing diosmin using water as a solvent, thanks to its patented process that offers more natural, sustainable and safe solutions for consumers.
Linked to this approach, HTBA recently received Zero Waste certification, granted by AENOR, verifying that the company valorises at least 90% of the waste it generates, preventing it from ending up in landfill.
"We’re always striving to achieve better solutions and processes that improve manufacturing sustainability and efficiency while helping to support health and wellbeing,” explains Ignacio Paco Ferreira, Chief Operations Officer at HTBA.
"Our new plant will not only increase production, but it will also equip us to improve our operating model through research-driven process innovation, digitalisation and energy efficiency."
"With improved and expanded production, we’re gearing up to better meet customer and consumer needs for the long-term, offering a consistent, reliable supply as a trusted source of high-quality diosmin for nutraceutical and pharmaceutical applications."
Earlier this year, HTBA announced the completion of a previous €25m investment project to modernise its research, development and manufacturing centre in Spain.
The initiative involved the construction of a new state-of-the-art production plant, making HTBA the only company in Europe capable of producing all active forms of vitamin B12, further reinforcing its status as a leader in the industry.